Back to results
US 2023/0405009 A1Published application
Methods for treating hematologic malignancies with amino-pyrrolopyrimidinone compounds
AssigneeMerck Sharp & Dohme Corp.
InventorsAnson K. Abraham, Mohammed Z. H. Farooqui, Patricia Marinello, Kapil Mayawala
Life of this patent
Estimating the term…
Abstract
The application relates to methods of treating a BTK mediated disorder, such as a hematological malignancy, comprising administering to a subject in need thereof a compound of Formula (I) or a pharmaceutically acceptable salt thereof, in an amount from about 80 mg to about 160 mg per day.
Claims23
A method of treating a BTK mediated disorder, comprising administering to a subject in need thereof a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, in an amount of about 80 to about 160 mg per day.
A method of treating cancer, comprising administering to a subject in need thereof a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, in an amount of about 80 mg per day, wherein the cancer is a hematological malignancy selected from chronic lymphocytic leukemia (CLL), Richter's Transformation (RT), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), primary central nervous system (CNS) lymphoma, secondary central nervous system (CNS) lymphoma, marginal zone lymphoma (MZL), Waldenström's macroglobulinemia (WM), acute myeloid leukemia (AML), multiple myeloma (MM), and pediatric sarcoma and pediatric brain tumors.
Dependencies are inferred from the claim text.